Logo image of LNSR

LENSAR INC (LNSR) Stock Price, Forecast & Analysis

USA - Nasdaq - NASDAQ:LNSR - US52634L1089 - Common Stock

11.63 USD
0 (0%)
Last: 12/31/2025, 8:12:23 PM
11.63 USD
0 (0%)
After Hours: 12/31/2025, 8:12:23 PM

LNSR Key Statistics, Chart & Performance

Key Statistics
Market Cap138.86M
Revenue(TTM)59.14M
Net Income(TTM)-51.52M
Shares11.94M
Float9.63M
52 Week High17.31
52 Week Low7.25
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-4.39
PEN/A
Fwd PEN/A
Earnings (Next)02-25 2026-02-25/bmo
IPO2020-09-21
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment


LNSR short term performance overview.The bars show the price performance of LNSR in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 -5 10 -10

LNSR long term performance overview.The bars show the price performance of LNSR in the last 1, 2 and 3 years. 1 year 2 years 3 years 50 100 150 200 250

The current stock price of LNSR is 11.63 USD. In the past month the price increased by 13.24%. In the past year, price increased by 34.45%.

LENSAR INC / LNSR Daily stock chart

LNSR Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABT ABBOTT LABORATORIES 25.11 217.86B
ISRG INTUITIVE SURGICAL INC 65.78 200.77B
BSX BOSTON SCIENTIFIC CORP 32.32 141.35B
SYK STRYKER CORP 26.69 134.41B
BDX BECTON DICKINSON AND CO 13.46 55.39B
IDXX IDEXX LABORATORIES INC 53.65 54.02B
EW EDWARDS LIFESCIENCES CORP 33.17 49.47B
GEHC GE HEALTHCARE TECHNOLOGY 17.87 37.36B
RMD RESMED INC 24.33 35.16B
DXCM DEXCOM INC 35.68 25.89B
PODD INSULET CORP 62.2 20.00B
ZBH ZIMMER BIOMET HOLDINGS INC 11.11 17.82B

About LNSR

Company Profile

LNSR logo image LENSAR, Inc. engages in the development of femtosecond laser technology for refractive cataract surgery. The company is headquartered in Orlando, Florida and currently employs 140 full-time employees. The company went IPO on 2020-09-21. The firm is focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. Its product portfolio includes the LENSAR Laser System (LLS), and the ALLY Robotic Cataract Laser Treatment System (ALLY). The firm has developed its ALLY Robotic Cataract Laser System as a compact, ergonomic system utilizing a fast dual-modality laser and integrating artificial intelligence (AI) into proprietary imaging and software. ALLY is designed to transform cataract surgery by utilizing the Company’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes its proprietary Streamline software technology, designed to guide surgeons to achieve better outcomes.

Company Info

LENSAR INC

2800 Discovery Drive, Suite 100

Orlando FLORIDA 32826 US

CEO: Nicholas Curtis

Employees: 140

LNSR Company Website

LNSR Investor Relations

Phone: 18885367271

LENSAR INC / LNSR FAQ

What does LENSAR INC do?

LENSAR, Inc. engages in the development of femtosecond laser technology for refractive cataract surgery. The company is headquartered in Orlando, Florida and currently employs 140 full-time employees. The company went IPO on 2020-09-21. The firm is focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. Its product portfolio includes the LENSAR Laser System (LLS), and the ALLY Robotic Cataract Laser Treatment System (ALLY). The firm has developed its ALLY Robotic Cataract Laser System as a compact, ergonomic system utilizing a fast dual-modality laser and integrating artificial intelligence (AI) into proprietary imaging and software. ALLY is designed to transform cataract surgery by utilizing the Company’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes its proprietary Streamline software technology, designed to guide surgeons to achieve better outcomes.


Can you provide the latest stock price for LENSAR INC?

The current stock price of LNSR is 11.63 USD.


Does LENSAR INC pay dividends?

LNSR does not pay a dividend.


What is the ChartMill rating of LENSAR INC stock?

LNSR has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


What is the analyst forecast for LNSR stock?

7 analysts have analysed LNSR and the average price target is 15.3 USD. This implies a price increase of 31.56% is expected in the next year compared to the current price of 11.63.


Can you provide the PE ratio for LNSR stock?

LENSAR INC (LNSR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.39).


LNSR Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to LNSR. When comparing the yearly performance of all stocks, LNSR is one of the better performing stocks in the market, outperforming 81.55% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

LNSR Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to LNSR. LNSR may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

LNSR Financial Highlights

Over the last trailing twelve months LNSR reported a non-GAAP Earnings per Share(EPS) of -4.39. The EPS decreased by -200.68% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -73.39%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%-138.46%
Sales Q2Q%5.74%
EPS 1Y (TTM)-200.68%
Revenue 1Y (TTM)21.02%

LNSR Forecast & Estimates

7 analysts have analysed LNSR and the average price target is 15.3 USD. This implies a price increase of 31.56% is expected in the next year compared to the current price of 11.63.

For the next year, analysts expect an EPS growth of -5.37% and a revenue growth 21.28% for LNSR


Analysts
Analysts45.71
Price Target15.3 (31.56%)
EPS Next Y-5.37%
Revenue Next Year21.28%

LNSR Ownership

Ownership
Inst Owners49.71%
Ins Owners19.38%
Short Float %8.2%
Short Ratio13.4